LifeMD (LFMD) Competitors

$4.78 +0.29 (+6.46%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$4.85 +0.07 (+1.46%)

As of 05/8/2026 06:22 PM Eastern

LFMD vs. OMDA, TALK, CSTL, EHAB, and PSNL

Should you be buying LifeMD stock or one of its competitors? The main competitors of LifeMD include Omada Health (OMDA), Talkspace (TALK), Castle Biosciences (CSTL), Enhabit (EHAB), and Personalis (PSNL). These companies are all part of the "healthcare" industry.

How does LifeMD compare to Omada Health?

Omada Health (NASDAQ:OMDA) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Omada Health presently has a consensus target price of $22.91, indicating a potential upside of 54.58%. LifeMD has a consensus target price of $9.14, indicating a potential upside of 91.27%. Given LifeMD's higher possible upside, analysts clearly believe LifeMD is more favorable than Omada Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omada Health	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
LifeMD	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

LifeMD has a net margin of 2.37% compared to Omada Health's net margin of -2.22%. Omada Health's return on equity of -1.85% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omada Health	-2.22%	-1.85%	-1.36%
LifeMD	2.37%	-150.88%	-22.59%

In the previous week, Omada Health had 4 more articles in the media than LifeMD. MarketBeat recorded 18 mentions for Omada Health and 14 mentions for LifeMD. Omada Health's average media sentiment score of 0.82 beat LifeMD's score of -0.17 indicating that Omada Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omada Health	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeMD	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

LifeMD has lower revenue, but higher earnings than Omada Health. Omada Health is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omada Health	$260.21M	3.38	-$12.78M	-$0.17	N/A
LifeMD	$193.33M	1.18	$14.35M	$0.05	95.60

35.5% of LifeMD shares are owned by institutional investors. 18.4% of LifeMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Omada Health beats LifeMD on 8 of the 15 factors compared between the two stocks.

How does LifeMD compare to Talkspace?

LifeMD (NASDAQ:LFMD) and Talkspace (NASDAQ:TALK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

35.5% of LifeMD shares are held by institutional investors. Comparatively, 57.4% of Talkspace shares are held by institutional investors. 18.4% of LifeMD shares are held by insiders. Comparatively, 23.5% of Talkspace shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Talkspace has a net margin of 3.40% compared to LifeMD's net margin of 2.37%. Talkspace's return on equity of 6.89% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Talkspace	3.40%	6.89%	5.87%

LifeMD has higher earnings, but lower revenue than Talkspace. LifeMD is trading at a lower price-to-earnings ratio than Talkspace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$193.33M	1.18	$14.35M	$0.05	95.60
Talkspace	$228.87M	3.80	$7.79M	$0.05	103.80

In the previous week, LifeMD had 5 more articles in the media than Talkspace. MarketBeat recorded 14 mentions for LifeMD and 9 mentions for Talkspace. Talkspace's average media sentiment score of 0.20 beat LifeMD's score of -0.17 indicating that Talkspace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Talkspace	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LifeMD has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, Talkspace has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

LifeMD currently has a consensus target price of $9.14, suggesting a potential upside of 91.27%. Talkspace has a consensus target price of $5.56, suggesting a potential upside of 7.18%. Given LifeMD's stronger consensus rating and higher probable upside, analysts clearly believe LifeMD is more favorable than Talkspace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Talkspace	0 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.11

Summary

Talkspace beats LifeMD on 9 of the 15 factors compared between the two stocks.

How does LifeMD compare to Castle Biosciences?

LifeMD (NASDAQ:LFMD) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

LifeMD currently has a consensus price target of $9.14, suggesting a potential upside of 91.27%. Castle Biosciences has a consensus price target of $46.00, suggesting a potential upside of 131.97%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Castle Biosciences is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Castle Biosciences	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are owned by institutional investors. 18.4% of LifeMD shares are owned by insiders. Comparatively, 6.1% of Castle Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

LifeMD has higher earnings, but lower revenue than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$193.33M	1.18	$14.35M	$0.05	95.60
Castle Biosciences	$344.23M	1.75	-$24.16M	-$0.44	N/A

LifeMD has a net margin of 2.37% compared to Castle Biosciences' net margin of -3.78%. Castle Biosciences' return on equity of -2.77% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Castle Biosciences	-3.78%	-2.77%	-2.30%

In the previous week, LifeMD had 1 more articles in the media than Castle Biosciences. MarketBeat recorded 14 mentions for LifeMD and 13 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 0.28 beat LifeMD's score of -0.17 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Castle Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

LifeMD has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Summary

Castle Biosciences beats LifeMD on 10 of the 17 factors compared between the two stocks.

How does LifeMD compare to Enhabit?

Enhabit (NYSE:EHAB) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

35.5% of LifeMD shares are held by institutional investors. 3.4% of Enhabit shares are held by company insiders. Comparatively, 18.4% of LifeMD shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

LifeMD has lower revenue, but higher earnings than Enhabit. Enhabit is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enhabit	$1.06B	0.67	-$4.60M	-$0.09	N/A
LifeMD	$193.33M	1.18	$14.35M	$0.05	95.60

Enhabit presently has a consensus price target of $13.57, suggesting a potential downside of 1.55%. LifeMD has a consensus price target of $9.14, suggesting a potential upside of 91.27%. Given LifeMD's stronger consensus rating and higher possible upside, analysts plainly believe LifeMD is more favorable than Enhabit.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enhabit	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
LifeMD	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

LifeMD has a net margin of 2.37% compared to Enhabit's net margin of -0.43%. Enhabit's return on equity of 4.71% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enhabit	-0.43%	4.71%	2.23%
LifeMD	2.37%	-150.88%	-22.59%

In the previous week, LifeMD had 11 more articles in the media than Enhabit. MarketBeat recorded 14 mentions for LifeMD and 3 mentions for Enhabit. Enhabit's average media sentiment score of 1.36 beat LifeMD's score of -0.17 indicating that Enhabit is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enhabit	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeMD	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Enhabit has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, LifeMD has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.

Summary

LifeMD beats Enhabit on 12 of the 16 factors compared between the two stocks.

How does LifeMD compare to Personalis?

Personalis (NASDAQ:PSNL) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

61.9% of Personalis shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 4.2% of Personalis shares are held by company insiders. Comparatively, 18.4% of LifeMD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

LifeMD has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	8.99	-$81.27M	-$0.91	N/A
LifeMD	$193.33M	1.18	$14.35M	$0.05	95.60

Personalis presently has a consensus price target of $11.50, indicating a potential upside of 92.31%. LifeMD has a consensus price target of $9.14, indicating a potential upside of 91.27%. Given Personalis' higher probable upside, equities analysts clearly believe Personalis is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
LifeMD	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

LifeMD has a net margin of 2.37% compared to Personalis' net margin of -148.11%. Personalis' return on equity of -45.98% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-148.11%	-45.98%	-34.30%
LifeMD	2.37%	-150.88%	-22.59%

In the previous week, LifeMD had 7 more articles in the media than Personalis. MarketBeat recorded 14 mentions for LifeMD and 7 mentions for Personalis. LifeMD's average media sentiment score of -0.17 beat Personalis' score of -0.31 indicating that LifeMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
LifeMD	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Personalis has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, LifeMD has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500.

Summary

LifeMD beats Personalis on 12 of the 16 factors compared between the two stocks.

Get LifeMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFMD vs. The Competition

Export

Metric	LifeMD	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$213.72M	$8.21B	$6.25B	$12.12B
Dividend Yield	N/A	2.89%	2.78%	5.20%
P/E Ratio	95.62	22.57	20.64	25.39
Price / Sales	1.18	17.56	534.02	75.96
Price / Cash	N/A	83.90	43.29	53.47
Price / Book	15.42	4.85	9.98	6.81
Net Income	$14.35M	$183.43M	$3.54B	$333.04M
7 Day Performance	-4.40%	0.60%	3.50%	3.15%
1 Month Performance	40.59%	6.08%	4.17%	7.12%
1 Year Performance	-42.13%	2.35%	41.85%	41.21%

LifeMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFMD LifeMD	3.5602 of 5 stars	$4.78 +6.5%	$9.14 +91.3%	N/A	$213.72M	$193.33M	95.62	230	Earnings Report Analyst Upgrade
OMDA Omada Health	3.0082 of 5 stars	$15.72 +2.8%	$21.64 +37.6%	N/A	$908.46M	$260.21M	N/A	849	Trending News Earnings Report Analyst Forecast
TALK Talkspace	2.3119 of 5 stars	$5.20 +0.2%	$5.56 +7.0%	N/A	$869.39M	$228.87M	104.02	500	Upcoming Earnings
CSTL Castle Biosciences	3.5489 of 5 stars	$25.52 +2.9%	$46.14 +80.8%	N/A	$751.64M	$344.23M	N/A	540	News Coverage Earnings Report Analyst Forecast
EHAB Enhabit	2.0653 of 5 stars	$13.75 0.0%	$13.57 -1.3%	N/A	$704.35M	$1.06B	N/A	10,800

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFMD) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LifeMD (LFMD) Competitors